Yang, 2022 |
China | ICIs (Camrelizumab or Sintilimab) | Gemcitabine + Cisplatin | 20 | 20 | 59 | 59 | 9:11 | 7:13 | OS, PFS, ORR, AEs | |
Yan, 2022 |
China | Gemcitabine |
Gemcitabine |
36 | 36 | NR | NR | 14:22 | 15:21 | OS | |
Sun, 2021 |
China | Gemcitabine + S-1 | Gemcitabine + Cisplatin + S-1 | 33 | 33 | NR | NR | NR | NR | OS, PFS, ORR, AEs | |
Gairing, 2021 |
Germany | Gemcitabine |
Gemcitabine |
14 | 59 | 61.3 | 66.8 | 8:6 | 29:30 | OS | |
Hu, 2020 |
China | Apatinib | Apatinib | 13 | 10 | 55.9 | 58.7 | 7:6 | 2:8 | OS, PFS, ORR, AEs | |
Verma, 2018 |
America | SYS | SYS | 666 | 2176 | 65 | 65 | 309:357 | 1095:1081 | OS | |
Chang, 2018 |
China | Fluoropyrimidine |
Fluoropyrimidine |
211 | 211 | 60.11 | 60.80 | 81:130 | 84:127 | OS | |
Konstantinidis, 2016 |
America | Gemcitabine |
Gemcitabine |
78 | 26 | 62 | 26 | 47:31 | 13:13 | OS, ORR | |
Edeline, 2015 |
France | Gemcitabine |
Gemcitabine + Cisplatin |
24 | 33 | NR | NR | NR | NR | OS, PFS | |
Kim, 2013 |
Korea | Capecitabine + Cisplatin | Capecitabine + Cisplatin | 25 | 67 | 56 | 58 | 6:19 | 14:53 | OS, PFS, ORR, AEs |